Share

Quotes

The feature of ISP by Biomedical Advances highlights that IRLAB is at the forefront of contemporary science. The brain, and disorders of the brain are complex and innovative approaches are needed to discover and develop treatments. By means of ISP we can continue our work to discover new, effective and safe, treatment strategies for these complex disorders.
Nicholas Waters, CEO
Both IRL752 and IRL790, IRLAB’s two development compounds in Phase II studies were discovered by ISP. Over the last few years, IRLAB has filed two new patent applications on compounds developed using ISP, and we expect to nominate an additional development compound within our P001 research programme shortly. This illustrates the efficiency of ISP and our organization.
Clas Sonesson, CMO
We are pleased that the planned UK Phase II study has rapidly received MHRA approval. There is a high interest among UK clinicians to participate in the study. We are looking forward to work with our UK colleagues and benefit from their extensive experience of clinical trials.
Joakim Tedroff, CMO
The approval from MHRA validates IRLABs technology by another independent competent authority. This supports the IRLAB capability to produce robust, international clinical drug candidates and projects.
Nicholas Waters, CEO
It is highly pleasing that yet another Competent Authority, the Finnish MPA, has reviewed our candidate drug IRL752 and given their clinical trial approval. Now the study can recruit patients in both Sweden and Finland. In addition, we get to collaborate with highly skilled Finnish experts with vast experience of Parkinson’s disease.
Joakim Tedroff, CMO
The approval from the MPA and the ethics committee is very encouraging. The Phase II study with IRL752 is a double-blind placebo controlled study in patients with Parkinson’s disease and dementia. About 80 % of all patients suffering from Parkinson’s disease develops symptoms of dementia which, today, lack satisfactory treatment.
Joakim Tedroff, CMO
The results from Phase 1 and Phase 1b studies in patients with Parkinson’s disease and levodopa-induced dyskinesia in Sweden is promising for the continued development of IRL790. We have recently completed a feasibility analysis in the UK and found that UK clinics have a high clinical competence regarding Parkinson’s disease, a large patient base, and interest in conducting the Phase 2 study. We are looking forward to working with our colleagues at TCTC who have an extensive experience from conducting international clinical trials in neurodegenerative diseases.
Joakim Tedroff, CMO
TCTC is delighted to work with IRLAB on this study. There is a huge unmet medical need to improve the lives of patients with Parkinson’s disease and IRL790 is an exciting new potential treatment for patients with Parkinson’s disease dyskinesia. We are very much looking forward to working with the IRLAB team and the UK investigators to deliver this important study.
Susan McGoldrick, TCTC CNS Project Director
The results from Phase 1 and Phase 1b studies in patients with Parkinson’s disease and levodopa-induced dyskinesia in Sweden is promising for the continued development of IRL790. We have recently completed a feasibility analysis in the UK and found that UK clinics have a high clinical competence regarding Parkinson’s disease, a large patient base, and interest in conducting the Phase 2 study. We are looking forward to working with our colleagues at TCTC who have an extensive experience from conducting international clinical trials in neurodegenerative diseases.
Joakim Tedroff, CMO
TCTC is delighted to work with IRLAB on this study. There is a huge unmet medical need to improve the lives of patients with Parkinson’s disease and IRL790 is an exciting new potential treatment for patients with Parkinson’s disease dyskinesia. We are very much looking forward to working with the IRLAB team and the UK investigators to deliver this important study.
Susan McGoldrick, TCTC CNS Project Director
Pick a time period -
There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe